INDEX:NBI Nasdaq Biotechnology Index
Well, that's the million dollar question. The multi-year move, unequivocally, has been one for the books, but propensity has shifted to the downside. name valuations are getting clipped, seemingly, on a daily basis, as investor de-risking broadens and continues heading into the psychological "sell in May" period. Included are several key support levels to watch (S-1 through S-5).